Lozano-Santos, Carol <br/><br/>
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.  [electronic resource] 

 -  Biochemical and biophysical research communications  May 2015 
 - 243-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1090-2104 
<br/><br/><label>Standard No.: </label>10.1016/j.bbrc.2015.04.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Arsenic Trioxide<br/>Arsenicals--pharmacology<br/>Drug Synergism<br/>Enzyme Inhibitors--pharmacology<br/>Female<br/>Growth Inhibitors--pharmacology<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Middle Aged<br/>Oxides--pharmacology<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Tumor Cells, Cultured<br/>Vidarabine--analogs & derivatives